Welcome to our dedicated page for CEL-SCI SEC filings (Ticker: CVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CEL-SCI Corporation filings document a clinical-stage biotechnology issuer funding the development of Multikine through registered securities offerings and reporting material corporate actions. Registration statements and prospectus-related filings describe common stock issuance capacity, use of proceeds for Multikine development, working capital, risk factors, operating and financial results, and the company's capital structure.
Current reports on Form 8-K record placement agency agreements, closed equity offerings, and amendments to the company's Shareholder Rights Agreement, including modifications to security-holder rights. The filing record also provides formal disclosure around governance, material agreements, and financing terms tied to CEL-SCI's cancer immunotherapy development business.
CEL-SCI Corporation is registering up to 3,440,367 shares of common stock, together with up to 3,440,367 pre-funded warrants and 3,440,367 underlying shares, in a best efforts primary offering. The assumed price is $4.36 per share, targeting approximately $13.7 million in net proceeds.
The company plans to use the cash mainly to fund development of its lead cancer immunotherapy Multikine and for general corporate purposes. CEL-SCI reports ongoing operating losses, including a $25.4 million net loss in fiscal 2025, has raised substantial doubt about its ability to continue as a going concern, and warns of significant dilution and risk given there is no minimum offering amount.
CEL SCI CORP Chief Scientific Officer Talor Eyal reported an acquisition of 747 shares of Common Stock on 2026-03-31. The shares were characterized as a grant, award, or other acquisition at a reported value of $3.21 per share. Following this transaction, Eyal directly holds 7,011 shares of CEL SCI CORP common stock.
PRICHEP PATRICIA B reported acquisition or exercise transactions in this Form 4 filing.
CEL-SCI Corp Chief Financial Officer Patricia B. Prichep received a grant of 1,336 shares of Common Stock on March 31, 2026. The grant is recorded at $3.21 per share and brings her direct holdings to 13,364 shares, reflecting a routine compensation-related equity award.
KERSTEN GEERT R reported acquisition or exercise transactions in this Form 4 filing.
CEL SCI CORP reported that Chief Executive Officer Geert R. Kersten received a stock grant of 1,682 shares of common stock on March 31, 2026. The grant was valued at $3.21 per share. Following this award, he directly holds 122,497 common shares.
CEL-SCI Corporation reported another loss-making quarter and reiterated serious liquidity risks. For the three months ended December 31, 2025, the company recorded a net loss of about $5.5 million, an improvement from $7.1 million a year earlier, as both research and development and general and administrative expenses declined.
Cash and cash equivalents fell to roughly $6.3 million from $11.0 million at September 30, 2025, driven mainly by operating cash outflows and lease payments. CEL-SCI has generated no product revenue and discloses “substantial doubt” about its ability to continue as a going concern without new financing.
The company remains focused on its lead cancer immunotherapy, Multikine, which in a prior Phase III study showed a five‑year survival rate of 73% in a defined head and neck cancer target population versus 45% in controls and a hazard ratio of 0.35. CEL-SCI plans a 212‑patient confirmatory registration study, estimated to cost $30–$35 million, and states that starting this trial depends on raising additional capital.
CEL-SCI Corp's Chief Executive Officer and director Geert Kersten purchased 38,023 shares of the company’s common stock on January 22, 2026 at $5.26 per share.
According to the filing, these were shares of restricted stock bought directly from the company at the closing price on January 21, 2026, which was the most recent closing price available. After this transaction, Kersten directly owns 120,815 shares of CEL-SCI common stock.
CEL-SCI Corporation's Chief Scientific Officer, Eyal Talor, reported a small open-market purchase of company stock. On 12/31/2025, he acquired 456 shares of common stock at a price of $5.26 per share. Following this transaction, he beneficially owns 6,264 shares of CEL-SCI common stock in direct ownership. This filing reflects personal share accumulation by a senior officer rather than a company-level financing or business event.
CEL-SCI Corporation's Chief Financial Officer, Patricia Prichep, reported acquiring additional common stock in the company. On 12/31/2025, she acquired 815 shares of CEL-SCI common stock at a price of $5.26 per share. Following this transaction, she beneficially owned 12,028 shares of CEL-SCI common stock in direct ownership. This insider transaction reflects a modest increase in the CFO’s personal stake in the company.
CEL-SCI Corp insider activity: Chief Executive Officer and Director Geert Kersten reported acquiring 998 shares of CEL-SCI common stock on 12/31/2025 at a price of $5.26 per share. Following this transaction, he beneficially owns 82,792 shares held directly.
CEL-SCI Corporation files its annual report describing late‑stage development of its lead cancer immunotherapy Multikine and its financial position. In a Phase 3 study target population, Multikine‑treated head and neck cancer patients showed a 5‑year survival of 73% versus 45% for controls, with a hazard ratio of 0.35 and supportive bias analyses. Regulators have allowed CEL-SCI to move forward with a 212‑patient confirmatory registration study, which the company estimates will cost about $30 million. CEL-SCI reports cumulative net losses of approximately $539 million through September 30, 2025 and cash and cash equivalents of about $11.0 million, and acknowledges substantial doubt about its ability to continue as a going concern without new capital. A 1‑for‑30 reverse stock split became effective in May 2025, and as of December 19, 2025 the company had 8,408,746 common shares outstanding.